Drug intelligence / Profile preview

AT299

Development stage: Preclinical
Lead developer: Arecor Therapeutics
Modality: Peptides
Administration: Subcutaneous

Overview

**AT299** is an Arecor-developed fixed-dose co-formulation of insulin and pramlintide, an amylin analogue, designed for diabetes management. The product is intended to combine insulin replacement with amylin-receptor agonism to improve postprandial glucose control, suppress inappropriate glucagon secretion, slow gastric emptying, and promote satiety. Arecor publicly described AT299 as a stable preclinical insulin-pramlintide co-formulation; it is distinct from the company's ready-to-use glucagon product for severe hypoglycemia.

Other names: insulin + pramlintide

Targets

INSR (Insulin receptor)AMY receptor (Calcitonin receptor (with ramps))

Beyond the preview

Go deeper on AT299.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT299.

Explore the full profile